| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
Anti-ulcer peptidergic agent
|
|---|---|
| ln Vitro |
Novel Gastric Peptide BPC157 has Cytoprotective effects in Gastrointestinal Tract and Cultured Enteric Neurons and Glial Cells[3].
|
| ln Vivo |
BPC 157 (10 μg/kg, 10 ng/kg) was injected intraperitoneally once a day (first application right after surgery, last application 24 hours prior to sacrifice) or dissolved in drinking water (0.16 μg/mL/12 ml/day till sacrifice) in a toxic rat model of multiple sclerosis. Control generally does not treat colostocolic anastomosis or cysteamine colitis. Both were effectively healed at the same time by BPC 157 [2].
|
| Cell Assay |
Body protection compound (BPC) 157 is a stable gastric pentadecapeptide. Predrag Sikiric’s team has carried out many investigations of its cytoprotective effects in different organs and tissues. Their evidence indicates that BPC157 has potent cytoprotection in neural injury and gastrointestinal (GI) ulcers. Nevertheless, the effects of BPC157 in the GI remain unclear. It is well known that the gut produces 95% of the 5-hydroxytryptamine (5-HT) in the human body. The 5-HT in the intestinal mucosa stimulates the production of pro-inflammatory mediators by immune cells. Enteric 5-HT may be a key player in physiological actions and the pathogenesis of intestinal inflammation. Previous evidence has shown that enteric 5-HT plays a prominent role in inflammatory bowel disease. The reports imply that BPC157 significantly modulates the regional synthesis of 5-HT in different areas of the rat brain. So far, the detailed mechanism of action of BPC157 has remained elusive in GI physiology and pathophysiology. Therefore, the aim of the study was to clarify the cytoprotective mechanism of BPC157 in the GI by investigating the release of enteric 5-HT, the survival rate of cultured enteric neurons, the proliferation of cultured enteric glial cells (EGCs), and intestinal motility with and without BPC157[3].
|
| Animal Protocol |
Stable gastric pentadecapeptide BPC 157 was suggested to link inflammatory bowel disease and multiple sclerosis, and thereby, shown to equally counteract the models of both of those diseases. For colitis, cysteamine (400 mg/kg intrarectally (1 ml/rat)) and colon-colon anastomosis (sacrifice at day 3, 5, 7, and 14) were used. BPC 157 (10 μg/kg, 10 ng/kg) was applied either intraperitoneally once time daily (first application immediately after surgery, last at 24 hours before sacrifice) or per-orally in drinking water (0.16 μg/ml/12 ml/day till the sacrifice) while controls simultaneously received an equivolume of saline (5 ml/kg) intraperitoneally or drinking water only (12 ml/day). A multiple sclerosis suited toxic rat model, cuprizone (compared with standard, a several times higher regimen, 2.5% of diet regimen + 1 g/kg intragastrically/day) was combined with BPC 157 (in drinking water 0.16 μg or 0.16 ng/ml/12 ml/day/rat + 10 μg or 10 ng/kg intragastrically/day) till the sacrifice at day 4. In general, the controls could not heal cysteamine colitis and colon-colon anastomosis. BPC 157 induced an efficient healing of both at the same time. Likewise, cuprizone-controls clearly exhibited an exaggerated and accelerated damaging process; nerve damage appeared in various brain areas, with most prominent damage in corpus callosum, laterodorsal thalamus, nucleus reunions, anterior horn motor neurons. BPC 157-cuprizone rats had consistently less nerve damage in all damaged areas, especially in those areas that otherwise were most affected. Consistently, BPC 157 counteracted cerebellar ataxia and impaired forelimb function. Thereby, this experimental evidence advocates BPC 157 in both inflammatory bowel disease and multiple sclerosis therapy[2].
|
| References |
[1]. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632.
[2]. Klicek R, et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. 2013;64(5):597-612. > [3]. Cytoprotective Mechanism of the Novel Gastric Peptide BPC157 in Gastrointestinal Tract and Cultured Enteric Neurons and Glial Cells. Neurosci Bull. 2019 Feb; 35(1): 167–170. |
| Additional Infomation |
Bepecin is under investigation in clinical trial NCT02637284 (PCO-02 - Safety and Pharmacokinetics Trial).
|
| Molecular Formula |
C62H98N16O22
|
|---|---|
| Molecular Weight |
1419.53552
|
| Exact Mass |
1418.704
|
| Elemental Analysis |
C, 52.46; H, 6.96; N, 15.79; O, 24.79
|
| CAS # |
137525-51-0
|
| Related CAS # |
216441-24-6 (sodium);137525-51-0;1628202-16-3 (TFA);
|
| PubChem CID |
9941957
|
| SequenceShortening |
GEPPPGKPADDAGLV
|
| Appearance |
Typically exists as white to off-white solids at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1802.9±65.0 °C at 760 mmHg
|
| Flash Point |
1044.2±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.576
|
| LogP |
-2.41
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
24
|
| Rotatable Bond Count |
39
|
| Heavy Atom Count |
100
|
| Complexity |
3040
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
NCCCCC(C(N1CCC[C@H]1C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(=O)O)C(C)C)=O)CC(C)C)=O)=O)C)=O)CC(=O)O)=O)CC(=O)O)=O)C)=O)=O)NC(CNC([C@@H]1CCCN1C([C@@H]1CCCN1C([C@@H]1CCCN1C([C@@H](NC(CN)=O)CCC(=O)O)=O)=O)=O)=O)=O
|
| InChi Key |
HEEWEZGQMLZMFE-RKGINYAYSA-N
|
| InChi Code |
InChI=1S/C62H98N16O22/c1-31(2)25-37(55(92)74-50(32(3)4)62(99)100)71-46(81)29-65-51(88)33(5)67-53(90)38(26-48(84)85)73-54(91)39(27-49(86)87)72-52(89)34(6)68-57(94)41-15-10-21-75(41)58(95)35(13-7-8-20-63)70-45(80)30-66-56(93)40-14-9-22-76(40)60(97)43-17-12-24-78(43)61(98)42-16-11-23-77(42)59(96)36(18-19-47(82)83)69-44(79)28-64/h31-43,50H,7-30,63-64H2,1-6H3,(H,65,88)(H,66,93)(H,67,90)(H,68,94)(H,69,79)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,92)(H,82,83)(H,84,85)(H,86,87)(H,99,100)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,50-/m0/s1
|
| Chemical Name |
L-Valine,
glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-
|
| Synonyms |
BPC 157; BPC-157; BPC157; Bpc 15; Bpc-15; Bpc15; Bpc 157; Bepecin; Bpc 15; Bpc157; Booly protection compound 15; L-Valine, glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-; Booly protection compound 15
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~70.45 mM)
DMSO : ~50 mg/mL (~35.22 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (1.76 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (1.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7045 mL | 3.5223 mL | 7.0445 mL | |
| 5 mM | 0.1409 mL | 0.7045 mL | 1.4089 mL | |
| 10 mM | 0.0704 mL | 0.3522 mL | 0.7045 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA